The up-to-date approach of parkinson's disease;A Parkinson-kór modern szemlélete

Lege Artis Medicinae

Volumn 20, Issue 12, 2010, Pages 825-829

  Hidasi, Eszter ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Aetiology; Diagnostic tests; Parkinson's disease; Pharmacotherapy and non pharmacotherapy; Symptoms

Indexed keywords

EID: 78951482957     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Davie CA. A review of Parkinson's disease. British Medical Bulletin 2008;86(1):109-27.
2. Dekker MC, Bonifati V, van Duijn CM. Parkinson's disease: piecing together a genetic jigsaw. Brain 2003;126:1722-33.
3. Cookson MR, Xiromerisiou G, Singleton A. How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. Curr Opin Neurol 2005;18:706-11.
4. Cilks WP, Abou-Sleiman PM, Gandhi S. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365:415-6.
5. Takáts A. A Parkinson-kór diagnosztikai kritériumai és differenciáldiagnosztikája. Clin Neurosci/ldeggy Szle 2003;56(5-6):144-54.
6. Micheli AW, Lewis SJG, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. Brain 2004;127(8):1693-705.
7. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002;249(Suppl3):lll1-lll5.
8. Braak H, Bohl JR, Müller CM, et al. The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006;21:2042-51.
9. Kones R. Parkinson's disease: Mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition. Nutr Clin Pract 2010;25(4):371-89.
10. Schapira AH, Olanow CW. Neuroprotection in Parkinson's disease. JAMA 2004;291:358-64.
11. Doty RL, Gölbe LI, McKeown DA, Stern MB, Lehrach CM, Crawford D. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology 1993;43:962-5.
12. Reichmann H. Clinical criteria for the diagnosis of Parkinson's disease. Neurodegener Dis 2010;7(5):284-90.
13. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Sieele-Richardson- Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994;57:278-84.
14. Parkinson study group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in Parkinsonism. Neurology 2000;55:15-42.
15. Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, et al. The role of radiotracer imaging in Parkinson's disease. Neurology 2005;64:208-15.
16. 18F-des- metoxyfallipride for the differentiation of idiopathic and noni- diopathic Parkinson syndromes. J Nuclear Med 2010;51(4):581-7.
17. Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59:999-1005.
18. Gaenslen A, Berg D. Early diagnosis of Parkinson's disease. Int Rev Neurobiol 2010;90C:81-92.
19. Guevara CA, Blain CR, Stahl D, Lythgoe DJ, Lein PN, Barker GJ. Quantitative magnetic resonance spectroscopic imaging in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Eur J Neurol 2010;(9):1193-202.
20. Foki T, Pirken W, Klinger N, Geisler A, Rah J, Steinkellner T, et al. FMRI correlates of apraxia in Parkinson's disease patients OFF medication. Exp Neurol 2010. Jul.24 Article in Press.
21. Nyholm D, Nilsson Remahl Al, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-23.
22. Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. J Clin Neuropharmacol 2003, 26:109-11.
23. Klivényi P, Vécsei L. Clinical studies on pramipexol retard. Clin Neurosci/ldeggy Szle 2010;63(5-6):171-4.
24. Hersh BP, Earl NL, Hauser RA, Stacy M. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. Mov Disord 2010;25(7):927-31.
25. Poewe W, Wenning GK. Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord 2000;15:789-94.
26. Leegwater-Kim J, Bortan E. The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging 2010;5:149-56.
27. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord. 2010;25(10): 1357-63.
28. Kovács N, Balás I, Llumiguano C, Aschermann Zs, Nagy F, Janszky J, et al. Mély agyi stimuláció: egy új perspektíva a mozgászavarok kezelésében. Lege Artis Med 2009;19(2):119-26.
29. Moro E, Lang AE. Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. Expert Rev Neurother 2006;6:1695- 705.
30. Moro E, Allert N, Eleopra R, Houeto JL, Phan TM, Stoevelaar H. A decision tool to support appropriate referral for deep brain stimulation in Parkinson's disease. J Neurol 2009;26(1):83-8.
31. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-19.
32. Fregni F, Pascal-Leone A. Technology insight: noninvasive brain stimulation in neurology - perspective on the therapeutic potential of rTMS and tDCS. Nat Rev Neurol 2007;3:383-93.